Patents by Inventor John Lowe

John Lowe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11987580
    Abstract: Provided herein are compounds and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of conditions associated with inhibition of HDAC (e.g., HDAC2). The compounds are bicyclic inhibitors of histone deacetylase, useful for treating neurological disorders, memory or cognitive function disorders or impairments, extinction learning disorders, fungal diseases or infections, inflammatory diseases, hematological diseases, neoplastic diseases, psychiatric disorders, and memory loss.
    Type: Grant
    Filed: December 22, 2021
    Date of Patent: May 21, 2024
    Assignee: Alkermes, Inc.
    Inventors: Nathan Oliver Fuller, John A. Lowe, III
  • Publication number: 20240108628
    Abstract: The present technology provides methods for treating pancreatic cancer using a MEK inhibitor and a CDK4/6 inhibitor. Also disclosed herein are methods for increasing patient responsiveness to chemotherapeutic and/or immunotherapeutic regimes for pancreatic cancer. Kits for use in practicing the methods are also provided.
    Type: Application
    Filed: April 24, 2023
    Publication date: April 4, 2024
    Inventors: Marcus Ruscetti, John P. Morris, IV, Scott Lowe
  • Publication number: 20240081937
    Abstract: An adjustable seal includes a first ring extending about an axis and including a plurality of first teeth. The adjustable seal also includes a second ring extending about the axis and including a plurality of second teeth. The first ring and the second ring cooperatively defining a passage extending along the axis. The adjustable seal has a locked configuration in which the second teeth engage the first teeth and prevent movement of the first ring relative to the second ring, and an unlocked configuration in which the first ring is able to rotate relative to the second ring. The adjustable seal also includes a flexible member attached to the first ring and the second ring. Rotation of the first ring relative to the second ring in the unlocked configuration of the adjustable seal causes the flexible member to extend across at least a portion of the passage defined by the first ring and the second ring.
    Type: Application
    Filed: January 10, 2022
    Publication date: March 14, 2024
    Inventors: Mohamed ZAYED, Chase HARTQUIST, Halle LOWE, John CASHIN
  • Patent number: 11912702
    Abstract: Provided herein are compounds and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of conditions associated with inhibition of HDAC (e.g,. HDAC2).
    Type: Grant
    Filed: December 22, 2021
    Date of Patent: February 27, 2024
    Assignee: Alkermes, Inc.
    Inventors: Nathan Oliver Fuller, John A. Lowe, III
  • Patent number: 11858939
    Abstract: This invention provides compounds that are inhibitors of HDAC2. The compounds (e.g., compounds according to Formula I, II or any of Compounds 100-128 or any of those in Tables 2 or 3) accordingly are useful for treating, alleviating, or preventing a condition in a subject such as a neurological disorder, memory or cognitive function disorder or impairment, extinction learning disorder, fungal disease or infection, inflammatory disease, hematological disease, or neoplastic disease, or for improving memory or treating, alleviating, or preventing memory loss or impairment.
    Type: Grant
    Filed: December 28, 2020
    Date of Patent: January 2, 2024
    Assignee: Alkermes, Inc.
    Inventors: Martin R. Jefson, John A. Lowe, III, Fabian Dey, Andreas Bergmann, Andreas Schoop, Nathan Oliver Fuller
  • Publication number: 20230250165
    Abstract: Purified recombinant polypeptides isolated from Chinese hamster ovary host cells, including antibodies, such as therapeutic antibodies, and methods of making and using such polypeptides are provided.
    Type: Application
    Filed: April 21, 2023
    Publication date: August 10, 2023
    Applicant: Genentech, Inc.
    Inventors: X. Christopher Yu, Saloumeh Kadkhodayan Fischer, Susan C. Fisher, John Lowe, Atia Naim, Ailen M. Sanchez, Christopher A. Teske, Martin Vanderlaan, Annamarie Amurao, Jayme Franklin, Corazon Victa
  • Publication number: 20220340558
    Abstract: Provided herein are compounds and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of conditions associated with inhibition of HDAC (e.g., HDAC2).
    Type: Application
    Filed: December 22, 2021
    Publication date: October 27, 2022
    Inventors: Nathan Oliver Fuller, John A. Lowe, III
  • Publication number: 20220340560
    Abstract: Provided herein are compounds and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of conditions associated with inhibition of HDAC (e.g,. HDAC2).
    Type: Application
    Filed: December 22, 2021
    Publication date: October 27, 2022
    Inventors: Nathan Oliver Fuller, John A. Lowe, III
  • Patent number: 11441521
    Abstract: A valve for m exhaust gas recirculation Mae in an engine includes a first barrel connectable to a first group of cylinders, a second barrel connectable to a second group of cylinders, and a center barrel between the first and second barrels and connectable to an intake of the engine, A poppet valve with two valve heads mounted on a valve stem is provided to open and close openings between the first and second barrels, with one of the valve beads of the poppet valve opening into the center barrel Vanes are provided in the center barrel to direct flow from the opening by the valve bead that opens into the center barrel toward the outlet opening.
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: September 13, 2022
    Assignee: VOLVO TRUCK CORPORATION
    Inventors: Jian Li, John Lowe
  • Publication number: 20220151992
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Application
    Filed: June 24, 2021
    Publication date: May 19, 2022
    Inventors: John A. Lowe, III, M. Amin Khan
  • Publication number: 20220139047
    Abstract: Many attempts at translating real-time events (e.g., sporting events) to augmented reality (AR)-based, extended or Data Processing Service and Technology Environment cross reality (XR)-based, or virtual reality (VR)-based experiences and environments rely upon mapping captured surface image data (such as video, pictures, etc.) of objects (e.g., balls, players, etc.) onto computer-modeled environments. This surface mapping results in imperfect and unsatisfactory virtual reality experiences for the viewer because the images and sounds do not perfectly correlate to the motion and states of the real-time objects and players. To solve this problem, and create an improved experience fo the virtual spectator, a more accurate and immersive virtual, extended, or aumented reality environment can be created by relying on data from a network system of sensors embedded throughout the real-time environment during the event in question.
    Type: Application
    Filed: February 28, 2020
    Publication date: May 5, 2022
    Applicant: SCORCHED ICE INC.
    Inventors: John LOWE, Bruce WRIGHT, Adile ABBADI-MACINTOSH
  • Patent number: 11286256
    Abstract: Provided herein are compounds and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of conditions associated with inhibition of HDAC (e.g,. HDAC2).
    Type: Grant
    Filed: May 21, 2020
    Date of Patent: March 29, 2022
    Assignee: Alkermes, Inc.
    Inventors: Nathan Oliver Fuller, John A. Lowe, III
  • Patent number: 11225490
    Abstract: The present invention relates to compounds of Formula I:
    Type: Grant
    Filed: September 6, 2019
    Date of Patent: January 18, 2022
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Laura Cook Blumberg, John A. Lowe, III, Orn Almarsson, Juan C. Alvarez, Tarek A. Zeidan
  • Patent number: 11225475
    Abstract: Provided herein are compounds and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of conditions associated with inhibition of HDAC (e.g., HDAC2).
    Type: Grant
    Filed: August 7, 2018
    Date of Patent: January 18, 2022
    Assignee: Alkermes, Inc.
    Inventors: Nathan Oliver Fuller, John A. Lowe, III
  • Patent number: 11225479
    Abstract: Provided herein are compounds and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of conditions associated with inhibition of HDAC (e.g., HDAC2).
    Type: Grant
    Filed: August 31, 2020
    Date of Patent: January 18, 2022
    Assignee: Alkermes, Inc.
    Inventors: Nathan Oliver Fuller, John A. Lowe, III
  • Publication number: 20210277007
    Abstract: This invention provides compounds that are inhibitors of HDAC2. The compounds (e.g., compounds according to Formula I, II or any of Compounds 100-128 or any of those in Tables 2 or 3) accordingly are useful for treating, alleviating, or preventing a condition in a subject such as a neurological disorder, memory or cognitive function disorder or impairment, extinction learning disorder, fungal disease or infection, inflammatory disease, hematological disease, or neoplastic disease, or for improving memory or treating, alleviating, or preventing memory loss or impairment.
    Type: Application
    Filed: December 28, 2020
    Publication date: September 9, 2021
    Inventors: Martin R. Jefson, John A. Lowe, III, Fabian Dey, Andreas Bergmann, Andreas Schoop, Nathan Oliver Fuller
  • Publication number: 20210276977
    Abstract: Provided herein are compounds of Formula I and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with histone deacetylases (HDAC).
    Type: Application
    Filed: July 12, 2019
    Publication date: September 9, 2021
    Inventors: Nathan Oliver Fuller, John A. Lowe, III
  • Publication number: 20210276978
    Abstract: Provided herein are compounds of the Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with histone deacetylases (HDAC).
    Type: Application
    Filed: July 12, 2019
    Publication date: September 9, 2021
    Inventors: Nathan Oliver Fuller, John A. Lowe, III
  • Patent number: 11077094
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: August 9, 2019
    Date of Patent: August 3, 2021
    Assignee: Aptinyx Inc.
    Inventors: John A. Lowe, III, M. Amin Khan
  • Publication number: 20210155632
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Application
    Filed: July 2, 2020
    Publication date: May 27, 2021
    Inventors: John A. Lowe, III, M. Amin Khan